High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

2000920 citationsJournal Article

Authors

John M. Kirkwood · Eastern Cooperative Oncology Group

Joseph G. Ibrahim · Eastern Cooperative Oncology Group

Vernon K. Sondak · Eastern Cooperative Oncology Group

Jon Richards · Eastern Cooperative Oncology Group

Lawrence E. Flaherty · Eastern Cooperative Oncology Group

Marc S. Ernstoff · Eastern Cooperative Oncology Group

Thomas J. Smith

Abstract

The results of the intergroup E1690 trial demonstrate an RFS benefit of IFNalpha2b that is dose-dependent and significant for HDI by Cox multivariable analysis.

Topics & Keywords

Cutaneous Melanoma Detection and Management CAR-T cell therapy research Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 18, Issue 12, pp. 2444-2458

DOI: 10.1200/jco.2000.18.12.2444

Field-Weighted Citation Impact: 27.32